Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T MacLaughlin

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 5, 2002
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivoDorry L Segev, Yasunori Hoshiya, Makiko Hoshiya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivoRafael Pieretti-Vanmarcke, Patricia K Donahoe, Paul Szotek, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2006
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancerRafael Pieretti-Vanmarcke, Patricia K Donahoe, Lisa A Pearsall, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2006
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessPaul P Szotek, Rafael Pieretti-Vanmarcke, Peter T Masiakos, et al.
Protein Expression and Purification|September 17, 2009
Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting SubstanceThanos D Papakostas, Rafael Pieretti-Vanmarcke, Fotini Nicolaou, et al.
International Journal of Oncology|May 9, 2009
The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasiaJae Yen Song, Keun Young Chen, Sue Yeon Kim, et al.
International Journal of Oncology|March 12, 2015
Transcriptome analysis reveals that Müllerian inhibiting substance regulates signaling pathways that contribute to endometrial carcinogenesisYoun Jee Chung, Hyun Jung Kim, Sang Ho Park, et al.
International Journal of Molecular Medicine|April 11, 2009
Identification of large-scale characteristic genes of Müllerian inhibiting substance in human ovarian cancer cellsSuk Woo Nam, Yun Sung Jo, Jung Woo Eun, et al.
International Journal of Oncology|May 17, 2011
Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cellsSeong Jin Hwang, Min Jung Suh, Joo Hee Yoon, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substanceKatia Meirelles, Leo Andrew Benedict, David Dombkowski, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|January 5, 2002
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivoDorry L Segev, Yasunori Hoshiya, Makiko Hoshiya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivoRafael Pieretti-Vanmarcke, Patricia K Donahoe, Paul Szotek, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2006
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancerRafael Pieretti-Vanmarcke, Patricia K Donahoe, Lisa A Pearsall, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2006
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessPaul P Szotek, Rafael Pieretti-Vanmarcke, Peter T Masiakos, et al.
Protein Expression and Purification|September 17, 2009
Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting SubstanceThanos D Papakostas, Rafael Pieretti-Vanmarcke, Fotini Nicolaou, et al.
International Journal of Oncology|May 9, 2009
The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasiaJae Yen Song, Keun Young Chen, Sue Yeon Kim, et al.
International Journal of Oncology|March 12, 2015
Transcriptome analysis reveals that Müllerian inhibiting substance regulates signaling pathways that contribute to endometrial carcinogenesisYoun Jee Chung, Hyun Jung Kim, Sang Ho Park, et al.
International Journal of Molecular Medicine|April 11, 2009
Identification of large-scale characteristic genes of Müllerian inhibiting substance in human ovarian cancer cellsSuk Woo Nam, Yun Sung Jo, Jung Woo Eun, et al.
International Journal of Oncology|May 17, 2011
Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cellsSeong Jin Hwang, Min Jung Suh, Joo Hee Yoon, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substanceKatia Meirelles, Leo Andrew Benedict, David Dombkowski, et al.
Pageof 5